To analyze the management challenges and outcomes of a case of bilateral Wilms tumor (BWT) with a TP53 mutation, highlighting the mutation's impact on treatment complexity.
Key Findings:
Bilateral Wilms tumor presents increased complexity and poorer prognosis compared to unilateral tumors, particularly in the presence of TP53 mutations.
TP53 mutations are associated with intrinsic chemoresistance and poor outcomes, necessitating alternative treatment strategies.
Despite guideline-concordant treatment, the patient experienced rapid disease progression and ultimately died, underscoring the need for improved therapeutic approaches.
Interpretation:
Current treatment protocols may not adequately address the challenges posed by high-risk molecular alterations like TP53 mutations, indicating a need for more tailored therapeutic strategies and further research.
Limitations:
The case highlights the limitations of histology- and stage-based treatment approaches for specific molecular subtypes, particularly in high-risk patients.
Further evidence from real-world clinical cohorts is needed to understand the impact of molecular markers on treatment response and to guide future therapeutic strategies.
Conclusion:
There is an urgent need for novel, biologically informed treatment approaches for high-risk bilateral Wilms tumor, particularly in patients with TP53 mutations, to improve outcomes.
